WCBA
AMGN icon

Weaver C. Barksdale & Associates’s Amgen AMGN Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Sell
5,857
-7
-0.1% -$2.4K 1.9% 20
2026
Q1 		$2.06M Buy
5,864
+350
+6% +$125K 1.97% 14
2025
Q4 		$1.81M Sell
5,514
-674
-11% -$214K 1.89% 20
2025
Q3 		$1.75M Sell
6,188
-389
-6% -$113K 1.68% 33
2025
Q2 		$1.84M Sell
6,577
-59
-0.9% -$16.7K 1.76% 27
2025
Q1 		$2.07M Sell
6,636
-154
-2% -$45.5K 1.98% 14
2024
Q4 		$1.77M Sell
6,790
-166
-2% -$49.3K 1.69% 29
2024
Q3 		$2.24M Sell
6,956
-259
-4% -$84.7K 2.02% 14
2024
Q2 		$2.25M Sell
7,215
-120
-2% -$35.3K 2.14% 9
2024
Q1 		$2.09M Sell
7,335
-45
-0.6% -$13.2K 1.91% 19
2023
Q4 		$2.13M Sell
7,380
-1,887
-20% -$514K 2.08% 13
2023
Q3 		$2.49M Buy
9,267
+1,531
+20% +$382K 2.12% 6
2023
Q2 		$1.72M Sell
7,736
-477
-6% -$111K 1.7% 33
2023
Q1 		$1.99M Sell
8,213
-398
-5% -$97.7K 1.86% 21
2022
Q4 		$2.26M Sell
8,611
-1,086
-11% -$291K 1.99% 15
2022
Q3 		$2.19M Sell
9,697
-613
-6% -$149K 2.19% 2
2022
Q2 		$2.51M Buy
10,310
+742
+8% +$182K 2.33% 1
2022
Q1 		$2.31M Buy
9,568
+127
+1% +$29.2K 2.06% 5
2021
Q4 		$2.12M Buy
+9,441
New +$1.99M 1.92% 18
2017
Q4 		$1.49M Sell
8,589
-86
-1% -$15.2K 1.57% 30
2017
Q3 		$1.62M Buy
8,675
+99
+1% +$17.5K 1.8% 9
2017
Q2 		$1.48M Hold
8,576
– – 1.72% 13
2017
Q1 		$1.41M Buy
8,576
+1,798
+27% +$299K 1.66% 27
2016
Q4 		$991K Buy
6,778
+1,068
+19% +$161K 1.6% 17
2016
Q3 		$952K Buy
5,710
+510
+10% +$86.2K 1.6% 20
2016
Q2 		$791K Hold
5,200
– – 1.37% 43
2016
Q1 		$780K Sell
5,200
-33
-0.6% -$4.9K 0.59% 68
2015
Q4 		$849K Buy
+5,233
New +$823K 0.66% 49

Other funds holding AMGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Weaver C. Barksdale & Associates's AMGN Position: Q2 2026 in Review

Weaver C. Barksdale & Associates reduced its Amgen (AMGN) stake by 0.12% in Q2 2026, selling an estimated $2.4K and leaving 5,857 shares worth $2.12M. The position accounts for 1.9% of the portfolio, ranked #20.

Weaver C. Barksdale & Associates first reported a position in AMGN in Q4 2015 and has held it in 28 quarters since. The position peaked at $2.51M in Q2 2022. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Weaver C. Barksdale & Associates held 5,857 shares of Amgen worth $2.12M as of Q2 2026.
  • Weaver C. Barksdale & Associates sold 7 Amgen shares in Q2 2026, an estimated $2.4K.
  • Amgen made up 1.9% of Weaver C. Barksdale & Associates's portfolio in Q2 2026, its #20 holding.
  • Weaver C. Barksdale & Associates first reported a position in Amgen in Q4 2015 and has held it in 28 quarters since.
  • Weaver C. Barksdale & Associates's Amgen position peaked at $2.51M in Q2 2022.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.